RBP4

Across TCGA pan-cancer cohorts, RBP4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RBP4 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBP4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RBP4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC and LUAD are the cancer types where RBP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.983	0.511	.004	32	view →
LUAD	DFS	Median	II,III,IV	0.236	0.726	.010	17	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RBP4–HNSC (DFS)

Open the HNSC breakdown →